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ABSTRACT
The MICAL (Molecules Interacting with CasL) proteins catalyze actin oxidation-
reduction reactions destabilizing F-actin in cytoskeletal dynamics. 
Here we show for the first time that MICAL2 mRNA is significantly over-expressed 
in aggressive, poorly differentiated/undifferentiated, primary human epithelial 
cancers (gastric and renal). Immunohistochemistry showed MICAL2-positive cells 
on the cancer invasive front and in metastasizing cancer cells inside emboli, but not 
at sites of metastasis, suggesting MICAL2 expression was 'on' in a subpopulation of 
primary cancer cells seemingly detaching from the tissue of origin, enter emboli and 
travel to distant sites, and was turned 'off' upon homing at metastatic sites.
In vitro, MICAL2 knock-down resulted in mesenchymal to epithelial transition, 
reduction of viability, and loss of motility and invasion properties of human cancer 
cells. Moreover, expression of MICAL2 cDNA in MICAL2-depleted cells induced 
epithelial to mesenchymal transition.
Altogether our data indicate that MICAL2 over-expression is associated with 
cancer progression and metastatic disease. MICAL2 might be an important regulator 
of epithelial to mesenchymal transition and therefore a promising target for  
anti-metastatic therapy.
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INTRODUCTION
The cure of most cancers will ultimately depend on 
the capability to eradicate disseminated secondary tumors 
that do not respond to therapy. Our current inability to 
do so motivates the search for target genes implicated in 
cancer progression. 
Cytoskeleton remodeling is a crucial event in 
metastasis progression because it is instrumental in 
regulating fundamental cell properties, from proliferation 
and/or differentiation to cell-cell and cell-substrate 
adhesion, motility and invasion. Tight regulation of actin 
dynamics relies on the activity of different actin-binding 
proteins controlling the transition from globular (G) to 
filamentous (F) actin, as well as nucleation, capping, 
severing, elongation and crosslinking of actin filaments 
[1, 2].
Recently, the family of Molecules Interacting with 
CasL (MICAL) [3, 4], was implicated in the regulation 
of actin cytoskeleton dynamics [5, 6]. MICALs have a 
unique structure that combines an N-terminal flavoprotein 
mono-oxygenase (MO) domain [7, 8] with other 
protein-protein interaction modules that network with 
cytoskeletal and signaling partners [3, 4]. Drosophila 
MICAL (D-MICAL) exerts oxidation-reduction (Redox) 
reactions to directly oxidize two methionine residues of 
actin, thereby destabilizing F-actin and inhibiting local 
assembly. D-MICAL activity is necessary for spatial 
guidance of the axonal growth cone, a highly motile 
sensory structure localized at the axon tip, essential for 
guiding neurons to their synaptic targets [9]. We reasoned 
that the striking capability of MICAL to directly and 
mechanistically connect oxygen availability with F-actin 
depolimerization and hence cytoskeleton dynamics 
might be extremely important also for metastatic cancer 
cells whose motility is increased as part of epithelial to 
mesenchymal transition (EMT). In fact, during the growth 
of solid tumors challenging micro-environmental factors 
(hypoxia, acidity, inflammatory cytokines, etc) stimulate 
cancer cells to enact escape adaptive strategies. Lead by a 
regulated genetic/epigenetic program, epithelial cells loose 
epithelial markers, cell-cell and cell-extracellular matrix 
(ECM) interactions, undergo cytoskeleton reorganization, 
gain gene expression profile, morphological and 
functional characteristics of mesenchymal cells, and 
leave the primary tumor site [10]. Both EMT and its 
opposite, mesenchymal to epithelial transition (MET), are 
implicated in developmental and pathological contexts 
[10]. During MET, mesenchymal markers are down-
regulated, cell motility decreases and cells adopt epithelial 
characteristics [10]. 
Up to now, MICALs involvement in human 
cancer was completely unexplored except for a report of 
MICAL2 splicing variants identified in prostate cancer 
[11]. While this work was in submission, it was published 
that MICAL-LIKE2, a protein of the MICAL family 
that shares sequence homology with MICAL2 but lacks 
the aminoterminal mono-oxygenase domain, is over-
expressed in ovarian cancer and when silenced induces 
MET in ovarian cancer cells [12].
Given the relevance of MICAL proteins to cell 
motility and the complete lack of information in the 
context of human primary cancer, we were compelled to 
understand whether MICAL2 activity might affect cancer 
cell motility and/or invasion activity, two properties 
crucial for determining the magnitude of cancer clinical 
effect. So we set out to investigate a possible involvement 
of MICALs in human epithelial cancer. We started with 
MICAL2 because of its basal activation not down-
regulated by self-inhibitory activity present in MICAL1 
and possibly in MICAL3 [13–15]. This feature suggested 
that deregulated expression might be sufficient to derange 
MICAL2 function, a trait in common to other actin-
binding proteins involved in cancer.
RESULTS
MICAL2 is variably expressed in human normal 
and cancer tissues
To search for novel genes involved in metastasis, we 
investigated the possible role of MICAL2 in cancer.
Interrogating web-based, expression databases we 
found MICAL2 mRNA variably and almost ubiquitously 
expressed in normal tissues, including stomach, lung 
and kidney (UniGene: http://www.ncbi.nlm.nih.gov/
UniGene/ESTProfileViewer.cgi?uglist = Hs.501928), 
with noticeable expression variations in several types 
of human cancer (IST Online: http://ist.medisapiens.
com/#ENSG00000133816), together with several outliers, 
also in lung and gastric cancer (GC), indicating possible 
patient subpopulations within each cancer type. In vitro, 
comparing MICAL2 mRNA z-score across the NCI-60 
panel, we found MICAL2 variably expressed in different 
cell lines (CellMiner: http://discover.nci.nih.gov/cellminer/
analysis.do). Interestingly, MICAL2 was down-regulated 
in epithelial-like breast cancer cells MCF7 and T47D, 
but up-regulated in breast cancer cells with mesenchymal 
features MDA-MB 231, BT-549 and HS578T.
We further explored the clinical significance of 
MICAL2 in human cancer performing comparative real 
time PCR (QRT-PCR) in normal/tumor paired biopsies 
of patients affected with three major types of human 
cancers: of the lung (non small cell lung cancer, NSCLC: 
Adenocarcinoma, AC; squamous cell carcinoma, SCC), 
kidney (clear cell renal cell carcinoma, ccRCC; papillary 
renal cell carcinoma, pRCC), and stomach (diffuse and 
intestinal histotypes).
In 27 NSCLC patients (11 AC, 16 SCC), we found 
statistically significant under-expression of MICAL2 
in SCC primary tumors compared with AC (p < 0.01, 
Figure 1A). We wondered whether it could be associated 
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with SCC lesser tendency to be invasive compared with 
AC, but this was not investigated further. 
MICAL2 was moderately to highly over-expressed 
in 6/8 pRCC patients (75%, Figure 1A). In 36 ccRCC 
primary samples, we found MICAL2 significantly over-
expressed in patients ‘with metastases’ versus ‘without 
metastases’ (p < 0.05, Figure 1B). 
Three histotypes of GC are described [16]: 
1) intestinal, (cancer cells are slow-growing, well 
differentiated, forming tubular or papillary gland 
structures), 2) diffuse (cancer cells are more aggressive, 
poorly differentiated, with a tendency to spread); 
3) mixed (with growing characteristics common to both 
diffuse and intestinal histotypes). In 30 GC samples, 
MICAL2 was found over-expressed in the diffuse histotype 
compared with intestinal and mixed histotypes together 
(p < 0.01, Figure 1C). Further, MICAL2 was found over-
expressed (p < 0.05) in samples of poorly differentiated 
and undifferentiated subtype G3 and G4 grade score 
(WHO criteria, [17]) as opposed to well and moderately 
differentiated G1 and G2 score [17], not shown. 
Overall, QRT-PCR showed MICAL2 up-regulation 
in poorly differentiated, aggressive tumor of the lung, 
kidney and stomach compared with paired normal tissues, 
and in association with metastasis.
MICAL2 is expressed at the cancer invasive 
front, and inversely correlates with expression of 
proliferation marker Ki-67 
To identify the cellular distribution of MICAL2 
expression, we performed immunohistochemistry (IHC) 
analyses of histological sections of gastric and kidney 
cancer, using specific anti-MICAL2 polyclonal antibodies 
generated in our laboratory (Supplementary Figure 1).
In GC, IHC showed a patchy distribution of 
MICAL2 over-expression in comparison with normal 
surrounding mucosa in 31/40 samples (77.5%). In diffuse, 
signet ring adenocarcinomas, MICAL2 expression was 
high within the tumor mass and in scattered neoplastic 
cells infiltrating the gastric wall (Figure 2A). Conversely, 
MICAL2 expression was undetectable in cancer cells of 
well differentiated, intestinal-type tumors (Figure 2B). 
MICAL2-positive cells were localized at the tumor 
infiltrating front (17/17 samples, 100%, Figure 2C 
left) rather than within the neoplastic core (p = 0.0001, 
Figure 2C right). Moreover, MICAL2-positive cells were 
found in neoplastic emboli (8/10 samples, 80%, Figure 2D 
left), where MICAL2 expression was higher than in the 
neoplastic core (p = 0.0038, Figure 2D right), and where 
sometimes it showed both nuclear and cytoplasmic 
localization. When variable differentiation grades were 
present within the same tumor, MICAL2 immunolabelling 
was higher in the less differentiated areas. Endothelial 
cells (ECs) of neo-angiogenic capillaries that extensively 
branch into the cancer mass showed a very intense 
MICAL2 immunostaining (Figure 2B), but no expression 
of MICAL1 and MICAL3 (Supplementary Figure 2), 
suggesting a different role of MICAL proteins within neo-
angiogenic ECs.
Given the peculiar localization of MICAL2-positive 
cells on the cancer invasive front, we wondered how 
this would correlate with the tumor cells proliferative 
state. Therefore, we analyzed the expression of Ki-67, 
a ubiquitous cell proliferation marker [18]. Consecutive 
sections from the same paraffin blocks were used for 
either immunostaining of MICAL2 or Ki-67. We found 
Ki-67 expression level inversely correlated with MICAL2 
expression (p < 0.05, Figure 2E).
In ccRCC, the subcellular localization of MICAL2 
was either cytoplasmic (Figure 3A), nuclear (Figure 3B), 
or both (Figure 3C) with cellular pattern variability 
within the same tumor. In addition, MICAL2 was highly 
expressed in ECs of the numerous cancer-associated 
capillaries (Figure 3D). Noticeably, MICAL2-positive 
neoplastic cells were detected within tumor emboli of 
lung metastases (Figure 3E) whereas, in the remaining 
cells of metastatic lesions to the brain (not shown) and 
lung (Figure 3F), MICAL2 protein expression was very 
low, localized to rare and scattered peripheral cells 
within the metastatic mass. MICAL2 protein was low 
in normal tubules and undetectable in normal glomeruli 
(Supplementary Figure 3).
Although it was not feasible to evaluate 
systematically and quantitatively the cancer invasive edge 
in the ccRCC samples available for this study, qualitative 
IHC analysis of single-antigen immunolabelling showed 
Ki-67 (Figure 3G) to be mainly expressed in the tumor 
core where MICAL2 (Figure 3H) was not or scarcely 
expressed, and vice versa (Figure 3I, 3J). So, MICAL2 
expression inversely correlated with proliferation also in 
kidney cancer.
Altogether, data showed MICAL2 expression 
was high in aggressive primary cancer and in metastatic 
emboli, but barely or not detectable in cancer cells at 
metastatic sites. 
Depletion of MICAL2 in cancer cells induces 
MET in vitro
With knock-down experiments, we investigated 
MICAL2 loss-of-function in human cancer cell lines with 
mesenchymal phenotype derived from kidney (786-O), 
breast (MDA-MB-231) and pleural cavity (MERO-14) 
respectively (generated as in Supplementary Figure 4). 
We performed RNA interference with commercial siRNA-
expressing plasmids, using three specific siRNAs for the 
target of interest, plus one non-specific siRNA and the 
corresponding empty vector as references. All through 
the text, cell lines are designated as follows: parental, 
untreated cancer cell lines as ‘WT’; cells transfected 
with control plasmid (either TRCN0000192634 or 
empty pLKO.1-Neo-CMV-tGFP) as ‘CTRL’ cells; 786-
O MIC2-KD clones as KD2 (obtained from tranfection 
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with a single plasmid, TRCN0000046581) and KD14 
(obtained from simultaneus transfection with three 
plasmids plasmids TRCN0000046579, TRCN0000046580 
e TRCN0000046581); MERO-14 MIC2-KD cells as 
KDM1; MDA-MB-231 MIC2-KD cells as KDM4. 
(KDM1 and KDM4 were obtained from transfection 
with all three plasmids). CTRL and parental cells are 
collectivey referred to as ‘reference’ cells. For details, see 
Materials and Methods and Supplementary Materials.
786-O MIC2-KD cells immediately appeared 
morphologically different (Figure 4), regardless of 
cell density in the culture plate (not shown). Instead of 
Figure 1: QRT-PCR gene expression analysis of MICAL2 in lung, kidney and stomach cancers. (A) MICAL2 deregulated 
expression in NSCLC (circles, N = 26), pRCC (squares, N = 8), ccRCC (triangles, N = 36) and GC (diamonds, N = 29). In NSCLC patients 
(10 AC and 16 SCC), MICAL2 is under-expressed in SCC (open circles, N = 16) in comparison to AC (thick circles, N = 10) patients. 
(B) MICAL2 mRNA level in ccRCC (N = 36) samples, against normal mucosa, was higher in patients with metastasis (triangles) in contrast to 
those without (circles). (C) In GC (N = 29), MICAL2 was over-expressed in Diffuse type (triangles) versus Intestinal or Mixed type (circles) 
samples. In all graphs, horizontal lines denote mean and SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 (Mann-Whitney non-parametric test).
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Figure 2: MICAL2 protein is abnormally expressed in primary human GC (IHC analysis). (A) Strong MICAL2-positive 
immunodecoration of the tumor, mostly as scattered neoplastic cells infiltrating the gastric wall (DAB stain, arrows). Scale bar: 50 μm. 
(B) Intestinal-type tumors showed very low to undetectable MICAL2 expression in cancer cells, but strong immunodecoration of neo-
angiogenic ECs (DAB staining, arrows). Scale bar: 100 μm. (C) MICAL2-positive cells (arrows) were found at the tumor infiltrating border 
rather than in the neoplastic core. Scale bar: 50 μm. MICAL2 mean expression level at the tumor infiltrating edge is higher than in the 
neoplastic core, N = 17, ***p ≤ 0.001 (Student’s T test for paired samples). (D) MICAL2-positive cells in neoplastic emboli (8/10, 80%). 
Scale bar: 20 μm. MICAL2 expression in emboli was higher than in the neoplastic core, N = 10, **p ≤ 0.01 (Student’s T test for paired 
samples). (E) Qualitative IHC analysis (images not shown) of single immunolabelling indicated Ki-67 expression level inversely correlated 
with MICAL2 expression. N = 10, r = –0.6641; p = 0.0181 (Pearson correlation test).
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Figure 3: MICAL2 is abnormally expressed in human kidney cancer. IHC analyses (DAB stain, arrows) showed MICAL2 
subcellular localization was (A) either cytoplasmic, (B) nuclear, (C) or both, scale bar: 20 μm. (D) Also in kidney cancer, MICAL2 was 
highly expressed in neo-angiogenic ECs. Scale bar: 50 μm. (E), Neoplastic emboli of metastases to the lung showed cells with intense 
MICAL2-positive immunodecoration (Scale bar: 100 μm), however (F) in the metastatic mass MICAL2 immunolabeling was very low and 
limited to rare, scattered peripheral cells (Scale bar: 50 μm). Representative images of cancer areas in which: (G) low expression of Ki-67 
was associated with (H) relatively high expression of MICAL2 (sample ID: 10190), and (I) relatively high expression of Ki-67 with (J) 
low/undetectable expression of MICAL2 in cancer cells, with expression localized to interstitium as evident from low magnification image 
(sample ID: 14587).
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the elongated, mesenchymal-like shape and scattered 
distribution on the plate, with minimal if any intercellular 
contacts, MIC2-KD cells appeared larger, organized 
in tightly packed clusters, with apico-basal polarity of 
epithelial cells (Figure 4A). 
Through its redox activity, D-MICAL is a direct 
regulator of F-actin dynamics in neural cells [4]. In 
non-neural cells, human MICALs are also regulators 
of actin stress fibers [13]. We stained F-actin to further 
characterize MIC2-KD phenotype, and observed a clearly 
different F-actin distribution (Figure 4B). Circumferential 
actin belts of individual cells, with abundant intracellular 
puncta, loss of prominent stress fibers, and presence of 
well-defined rims, indicative of cell-cell junctions in 
polarized cells of epithelial sheets [19], were visible in 
MIC2-KD cells, whereas reference cells (CTRL and 
parental) presented stress fibers and scarse pericellular 
F-actin, in agreement with [13].
To test the hypothesis that MICAL2 down-regulation 
leads to MET, we performed immunocytochemistry (ICC) 
analysis of typical epithelial markers of cell-cell contact, 
such as Zonula Occludens 1 (ZO-1) at tight junctions, 
E-cadherin and catenin-beta (CTNNB1) at adherens 
junctions. These markers were found sharply localized 
at cell-cell junctions in MIC2-KD cells, designing finely 
honed cell perimeters, typical of epithelial cells, rather than 
diffusely distributed in the cytoplasm as in mesenchymal-like 
reference cells (Figure 4B). Also, MIC2-KD cells showed 
short and disorganized vimentin filaments, compared with 
the longer meshes observed in control cells (Figure 4B). 
Vimentin and CTNNB1 expression was analyzed also by 
Western blot (WB). In MIC2-KD cells, CTNNB1 level was 
found strongly decreased (Figure 4C); WB anti-vimentin 
performed with V9 antibody (an anti-vimentin antibody 
different from that used for IF) did not yield any signal, as if 
the corresponding epitope was undetectable.
Signaling pathways activated by intrinsic or extrinsic 
stimuli responsible for eliciting EMT/MET converge 
on transcription factors (TFs) ultimately regulating the 
phenotypic changes, like Snail family zinc finger (SNAI)1 
and SNAI2 that impart mesenchymal traits to tumor cells 
including increased motility and invasiveness, and are 
responsible for transcriptional repression of E-cadherin 
[20, 21]. With QRT-PCR the expression of both SNAI1 
and SNAI2 resulted undetectable in KD2 and KD14 cells 
(Figure 4D).
Further, over-expression of MICAL2-tagged cDNA 
(HA-MICAL2) in flat, cobblestone-like, MICAL2-
depleted, KD14 cells produced motile, fibroblast-like cells 
(Figure 4E, 4F), resulting in the rescue of the mesenchymal 
phenotype of parental 786-O cells. To describe the cell 
shape change, we performed a quantitative morphometric 
analysis of cell perimeter, and characterized cell shape with 
circularity analysis. 786-O reference cells showed a more 
elongated phenotype (mean circularity values of 0.326 
and 0.285 respectively) compared with the two MIC2-
KD cell lines (mean circularity values of 0.651 for KD2 
and 0.621 for KD14, Figure 4E). Dividing the population 
of transfected MIC2-KD14 cells into two groups of low-
fluorescence and high-fluorescence cells (HA-MICAL2low 
and HA-MICAL2high) as monitored by IF with anti HA-
tag antibody, we also noticed a more elongated phenotype 
with dose-dependency on HA-MICAL2 expression (mean 
circularity values of 0.244 for HA-MICAL2low and 0.116 
for HA-MICAL2high, Figure 4E). 
Knocking-down MICAL2 reduces cell viability, 
adhesion and motility on 2D surfaces, and 
invasion properties in 3D matrices of cancer cells 
in vitro
To investigate how MIC2-KD affected basic cellular 
mechanisms like proliferation, cell adhesion, migration 
and invasion, we performed viability and functional assays 
in 786-O, MDA-MB-231 and MERO-14 cells. MTT-based 
cell-growth assays and manual counting showed that 
reducing MICAL2 mRNA level significantly decreased 
786-O and MERO-14 cell viability (Figure 5A, 5B). Since 
cell adhesion and motility play a key role during EMT, and 
MICAL2 has been implicated in growth cone dynamics 
[3, 9], we asked whether MICAL2 expression might affect 
cancer cell adhesion in vitro. On type-I collagen-coated 
plates, 786-O KD2 and KD14 cells showed 33% reduction 
in adhesion capacity (Figure 5C), and similar results were 
obtained with MERO-14 KDM1 cells (reduction of 30%, 
Figure 5D).
Further, a chemotaxis assay showed KD2 and 
KD14 cells were not able to cross the blind-well 
chamber membrane, even in the presence of 10% FBS 
(Figure 6A). We also performed a random 2D migration 
(chemokinesis) assay by plating cells in the presence of 
a diffuse chemokinetic stimulating agent (10% FBS). 
Time-lapse microscopy showed persistent migration by 
786-O reference cells when observing single-cell traces 
obtained during the 15 hr experiments, while KD2 and 
KD14 cells almost did not leave the origin (Figure 6B and 
Supplementary Movies). MIC2-KD cells moved randomly 
(Figure 6C) and more slowly (Figure 6D). We also observed 
a different behavior of the lamellipodia (Figure 6E, 6F). 
Reference cells migrated by extending dynamic protrusions 
with polarized and persistent lamellipodia, well-defined 
trailing and leading edges. In contrast, most MIC2-KD cells 
showed dynamic but irregularly shaped lamellipodia, often 
broader, almost circular, from which multiple, small, narrow 
and highly dynamic protrusions sticked out (Supplementary 
Movies and Figure 6E). This quasi radial ‘symmetrization’ 
of the cell motility apparatus resembled closely the ‘stop 
signal’ caused by prolonged contact [22], although in 
this case at the presence of very few surrounding cells. 
These results suggested MICAL2 abatement changed 
cell membrane protrusion morphology and behavior, and 
consequently net cell movement in 2D migration.
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Figure 4: Abating MICAL2 in 786-O kidney cancer cells in vitro induces MET. (A), Morphological analysis in light-transmitted 
microscopy. Scale bar: 100 µm. (B), F-actin staining. IF of: E-cadherin, ZO-1, catenin-beta. In KD2 and KD14 cells, these three markers 
relocated at cell perimeters (as in epithelial cells), rather than being diffusedly cytoplasmic. IF of vimentin with Vim13.2 antibody. In 
MIC2-KD cells it decorated short and disorganized filaments instead of long meshes observed in control cells. Scale bar of all IF images: 
20 µm. Inset magnification: 3x. (C), Vimentin epitope recognized by V9 antibody was undetectable in KD2 and KD14 cells. (D), Agarose 
gel run of SNAI1, SNAI2, 18s5 RT-PCR products. (E), KD14 cells transfected with HA-MICAL2 cDNA. The elongated phenotype showed 
dose-dependency on HA-MICAL2 expression. One-way Anova test and Tukey's Multiple Comparison post-hoc test. In all graph bars, 
horizontal lines denote mean and SEM. N.s: non significant. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). (F), MIC2-KD14 cells expressing HA-
MICAL2 (shown by anti-HA immunostaining) recovered a mesenchymal-like phenotype with concomitant F-actin redistribution.
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Since several primary carcinoma specimens showed 
MICAL2-positive cells on the cancer invasive edge and 
in intravasal tumor emboli (Figure 2C, 2D), we tested 
the contribution of MICAL2 to invasive properties of 
cancer cells in vitro. We performed invasion assays with 
786-O and MDA-MB-231 cells in 3D collagen matrix 
to characterize the migratory properties of cancer cells 
challenged to overcome the stiffness inherent to the 
surrounding matrix, a condition absent in 2D migration.
In 3D spheroid invasion assay, kidney cancer 
KD2 and KD14 cells were totally unable to invade the 
surrounding matrix during the 72 hr-experiment. Breast 
cancer cells KDM4 also showed reduction of invasion 
capacity (Figure 7B).
In vertical 3D invasion assay, 786-O MIC2-KD cells 
run only 33% of the average distance of cell migration 
above 20 μm performed by reference cells (Figure 7C). 
Altogether, these results suggested MICAL2 activity is 
necessary to confer cells the ability to detach from an 
origin and move within a complex 3D matrix.
MICAL2 is implicated in radical oxygen species 
(ROS) production in cancer cells
MICAL proteins display an N-terminal MO 
domain which binds flavin-adenine-dinucleotide 
(FAD) and uses the coenzyme nicotinamide-adenine-
dinucleotide-phosphate (NADPH) in redox reactions to 
Figure 5: Depleting MICAL2 reduces cancer cells viability and adhesion in vitro. MIC2-KD cells showed significantly 
decreased viability compared with respective (A) 786-O and (B) MERO-14 WT and CTRL cells. MIC2-KD reduced adhesion of KD2 and 
KD14 (33%, (C) and KDM1 (30%, (D) cells on type-I collagen. One-way Anova test and Tukey’s Multiple Comparison post-hoc test. In 
all graph bars, horizontal lines denote mean and SEM. N.s.: non significant. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Figure 6: MICAL2 abatement in vitro reduces motility of 786-O ccRCC cells. (A) Transwell migration assay: MIC2-KD 
cells were not able to cross the 10 µm-pore membranes of blind-well chambers, even in the presence of 10% FBS. Lower panel: result 
of a representative experiment. (B) Single-cell traces of 15-hr chemokinesis assay: KD2 and KD14 cells run an extremely short distance. 
Directness (C) and Velocity (D), indicators of oriented movement, were reduced. (E) (F)-actin staining with Phalloidin. Scale bar: 20 µm. 
Inset magnification: 3.7X. F, Fluorescence intensity derived from Phalloidin staining is measured for 2 µm across the cell border; negative 
distances are meant from the outer side of the contour toward the inner cell side. The peculiar peak of fluorescence intensity, occurring 
within the first µm away from the leading edge of lamellipodia in reference cells, was lost in KD2 and KD14 cells. A, C and D: One-way 
Anova test and Tukey’s Multiple Comparison post-hoc test. In all graphs, horizontal lines denote mean and SEM. N.s.: non significant. 
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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either directly oxidize substrate proteins and signaling 
molecules and/or produce ROS [5, 7, 8]. ROS in 
general and H2O2 in particular were associated with 
EMT induction and sustenance [23]. Therefore, we 
tested the hypothesis that reducing MICAL2 might 
affect ROS production. 786-O WT, CTRL, KD2 and 
KD14 cells were treated for 30 minutes with 25 uM 
2′, 7′-dichlorodihydrofluorescein diacetate (H2DCFDA), 
a cell-permeant ROS probe which is converted in the 
fluorescent 2′, 7′-dichlorodihydrofluorescein (H2DCF) 
upon oxidation within the cell. Cells were then live 
imaged with a fluorescent microscope to detect H2DCF 
fluorescence (Figure 8). A three to four folds H2DCF 
fluorescence reduction was found in MIC2-KD clonal 
lines.
We concluded that MICAL2 activity participates 
to ROS production, which is in agreement with current 
literature showing MICAL2-dependent ROS level increase 
in HeLa cells over-expressing MICAL2 [13].
DISCUSSION
To search for novel metastatic factors, we 
investigated a possible role in cancer for MICAL2, a 
Figure 7: MICAL2 abatement strongly reduces cancer cell 3D invasion properties. (A) Representative result of 3D spheroid 
invasion assay. (B) KDM4 showed reduced invasion activity. (C) Right: representative result of vertical 3D assays. One-way Anova test 
and Tukey’s Multiple Comparison post-hoc test. In all graphs, horizontal lines denote mean and SEM. N.s.: non significant. *p ≤ 0, 05, 
**p ≤ 0, 01, ***p ≤ 0, 001.
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protein involved in controlling cytoskeleton plasticity, a 
trait extremely relevant to cell rearrangements and motility 
in metastatic dissemination.
We found MICAL2 significantly over-expressed 
in poorly differentiated and undifferentiated gastric 
and kidney cancer, compared with more differentiated 
carcinomas. In ccRCC patients, MICAL2 over-expression 
was significantly associated with metastasis (Figure 1). 
All observations in primary and metastatic human 
tumors suggested that MICAL2 expression is ‘on’ in a 
subpopulation of primary cancer cells seemingly detaching 
from the origin and prone to actively migrate, in individual 
mode, resist anoikis and travel to distant sites. In brief, are 
in a state of EMT. In fact, recent data show that MICAL2 is 
part of a gene signature that specifically characterize high-
grade tumors bearing mesenchymal markers [24]. MICAL2 
is then turned ‘off’ following homing at the metastatic 
site, where MET occurs. The hypothesis of an ‘on-off’ 
expression mode during cancer progression, sustained by our 
in vitro functional analysis, is in line with current literature 
supporting that cancer spreading depends on mesenchymal-
like cells located on the cancer invasive front [10, 25]. 
This matches well with previous studies showing 
that loss of epithelial markers, like E-cadherin, and gain 
of mesenchymal markers, like vimentin (both events 
observed in our in vitro studies) can promote intravasation 
and early steps of metastasis, but then re-epithelialization 
is necessary for proliferation of disseminated cells at 
metastatic sites [26, 27]. 
Also the inverse correlation with Ki-67 expression 
level suggested that MICAL2 expression might occur in 
relatively few (compared with the tumor mass) but critical 
cells endowed with a motile, invasive phenotype at the 
tumor edge, rather than proliferating in situ. 
So MICAL2 is probably turned on by specific 
stimuli in the cancer microenvironment and its expression, 
after having accompanied/sustained cancer cell migration, 
is turned off at the metastatic site where the intensity of 
those signals has faded. This allows MET and reprise of 
proliferation. Consistently, MIC2-KD cells showed in 
vitro a coherent image of MET revealed by the dramatic 
reorganization of F-actin and by molecular analysis of 
indicative markers [28, 29] such as E-cadherin, ZO-1, 
CTNNB1 and vimentin (Figure 4B), suggesting indirectly 
Figure 8: MICAL2 is implicated in radical oxygen species (ROS) production in cancer cells. (A) Detectable ROS levels 
were present in WT and CTRL cells, by contrast a three to four folds reduction in H2DCF fluorescence in the MIC2-KD clonal lines was 
found. (One-way Anova test and Tukey’s Multiple Comparison post-hoc test. Horizontal lines denote mean and SEM. Ns: non significant. 
*p ≤ 0, 05, **p ≤ 0, 01, ***p ≤ 0, 001). (B) representative micrographs showing H2DCF fluorescence in 786-O WT, CTRL, KD2 and KD14 
cells (left) and binary mask created in ImageJ by applying a threshold, to visualize cell boundaries (right).
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that MICAL2 regulated function is necessary for formation 
of proper cell-cell junctions. Interestingly, vimentin 
and CTNNB1 over-expression and/or cytoplasmic 
accumulation (as we found in cancer cells expressing high 
level of MICAL2 in vitro) are both known predictors of 
hematogenous metastasis in human cancer [30, 31]. 
MET in MIC2-KD cells occurred through 
transcriptional reprogramming, indicated by the decrease/
loss of expression of SNAI1 and SNAI2 (Figure 4D), two 
TFs crucial in initiating/maintaining EMT [19–21]. How 
this happens was not addressed in this work but, based 
on information about other MICAL family members 
[14, 32–36], MICAL2 might take part in vesicular 
trafficking required for transfer of cell surface receptors 
or other cell signaling event. 
Furthermore, when we reconstituted MICAL2 
expression by cDNA transfection in MIC2-KD cells, that 
have epithelioid phenotype, we obtained a mesenchymal 
phenotype (Figure 4E, 4F). On one hand this supported 
the specificity of the results of our knock-down approach 
and, on the other, more importantly, suggested that the 
expression/re-expression of MICAL2 is sufficient to 
induce EMT in epithelial cells.
Overall, all MIC2-KD cell populations generated 
from cancer cells of different histotypes were found 
less adherent (Figure 5) and noticeably less capable of 
migrating (Figure 6) and invading (Figure 7) in 2D and 
3D assays in vitro, consistently with a MET phenotype. 
Directional migration requires cell polarity, but MIC2-KD 
cells lacked a clearly polarized arrangement in 2D and 3D 
assays, suggesting that in cancer MICAL2 endogenous 
over-expression might promote invasion. Often, in 
metastatic cancers other actin-modifying enzymes were 
found expressed in deregulated ways. Although that is 
not a cancer-initiating event it can certainly be a cancer-
promoting factor, because expression normalization can 
revert the metastatic phenotype [38]. 
Finally, it was proposed that in addition to directly 
modifying F-actin through redox reactions, MICALs may 
influence intracellular signaling through generation of 
ROS as second messengers, in a physiologically restricted 
manner [9]. ROS have per se notorious pro-metastatic, 
pro-neoangiogenic effects. Our data showing sharp 
decrease of ROS production in MIC2-KD cells suggest that 
endogenous over-expression of MICAL2 in human cancer 
might generate high ROS level with a consequent cell-
autonomous, pro-metastatic, pro-angiogenic effect during 
EMT. MIC2-KD might contribute to ROS decrease and 
MET also through inhibition of SNAI1, whose expression 
increases ROS level in cancer cells leading to EMT [39]. 
In conclusion, this is the first work to show data 
from human cancer and in vitro analyses suggesting that 
MICAL2 represents a marker of metastatic disease that 
promotes migration and invasion of epithelial cancers. 
MICAL2 might represent a new therapeutic target for 
thwarting epithelial cancer cell pro-invasive and pro-
metastatic potential.
MATERIALS AND METHODS
Tissue specimens
Human paired tumor/normal tissue samples were 
retrospectively obtained from patients who underwent 
surgery with curative or palliative intent for primary 
gastric cancer (N = 64) at the Department of Pathological 
Anatomy of Azienda Ospedaliera Universitaria Senese 
(Siena, Italy) and the Department of General Surgery 
and Oncology (University of Siena, Italy), and for lung 
(N = 27 NSCLC) and kidney cancer (N = 36 ccRCC) at 
the Blokhin Cancer Research Center (Russian Academy of 
Medical Sciences, Moscow, Russia). The study was done 
in accordance with the Declaration of Helsinki. Approval 
was obtained from pertinent ethics committee. All 
patients gave informed written consent. Patients who had 
undergone pre-operative radiotherapy or chemotherapy 
were excluded. Samples were taken in the operating room 
and stored in liquid nitrogen. In addition to the tumor, a 
sample of paired normal tissue was collected from the 
operative specimens at least 10 cm from the tumor, when 
applicable. Only samples containing 70–80% or more 
tumor cells, and adjacent specimens, fixed in formalin and 
embedded in paraffin, were used.
Diagnosis and histological grading were assessed 
using standard criteria by experienced pathologists. Renal 
cell carcinomas were classified and graded according 
to [17] and staged according to [40]. Gastric cancers 
were classified in intestinal, diffuse and mixed histotype 
according to [16] and staged according to [40]. 
Cell lines and culturing
786-O (ATCC CRL-1932), and MDA-MB-231 
(ATCC HTB-26) were purchased from ATCC-LGC 
Standards (Eu), MERO-14 from Sigma. 
Cell lines were purchased ad hoc for the study 
and kept in appropriate growth medium additioned with 
100 IU/ml penicillin, 100 μg/ml streptomycine: 786-O in 
RPMI-1640 (Sigma-Aldrich) with 10% heat-inactivated 
fetal bovine serum (FBS, Gibco), 10 mM HEPES, 
1 mM Na pyruvate, 100 mM glutamine; MDA-MB-231 
in RPMI-1640 (Sigma-Aldrich) with 10% FBS (Gibco), 
100 mM glutamine; MERO-14 in DMEM (Sigma-
Aldrich) with 15% FBS (Gibco), 200 mM glutamine. 
All cell cultures were kept in 5% CO2 incubator at 37°C, 
and routinely tested for mycoplasma contamination 
(MycoAlert Kit, Lonza).
In silico analysis
Public bioinformatic resources used for this study: 
http://www.ncbi.nlm.nih.gov/unigene/, http://www.cbs.dtu.
dk/services/NetPhos/, http://web.expasy.org/findmod/, http://
rsbweb.nih.gov/ij/index.html, http://www.genesapiens.org/, 
http://discover.nci.nih.gov/cellminer/analysis.do.
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RNA and cDNA preparation for 
retrotranscription-PCR (RT-PCR) and  
semi-quantitative real time-PCR (QRT-PCR)
Total RNA was isolated with RNeasy Mini Kit 
(Qiagen). Purified total RNA samples were quantified 
spectrophotometrically (NanoDrop ND-1000, NanoDrop 
Technologies, USA), and quality-checked (Bioanalyzer 
2100, Agilent Technologies, USA). cDNA was synthesized 
using random hexamers and oligo-dT primers (QuantiTect 
Reverse Transcription Kit, Qiagen).
RT-PCR was performed in 2720 Thermal Cycler 
(Applied Biosystems, USA), with GoTaq Flexi DNA 
Polymerase (Promega). QRT-PCR was performed in 
technical and when applicable biological triplicates, in ABI 
7000 PRISM SDS thermal cycler (Applied Biosystems). 
Data were analyzed through relative quantification with 
the –ΔΔCt method. 
Sequence of primers: EEF1A1 (NM_001402.5): 
5′-CTTTGGGTCGCTTTGCTGTT-3′, 5′-CCGTTCTTC 
CACCACTGATT-3′; GAPDH (NM_001289746.1); 5′-GC 
TCATTTCCTGGTATGACAACG-3′, 5′-AGGGGTCTAC 
ATGGCAACTG-3′; beta-actin (NM_001101.3): 5′-AACT 
GGAACGGTGAAGGTGACAGC-3′, 5′-AGAAGTGG 
GGTGGCTTTTAGG-3′; PPIA (NM_021130.3): 5′-TTC 
ATCTGCACTGCCAAGAC-3′, 5′-TCGAGTTGTCCACA 
GTCAGC-3′; 18S5 (NR_003286.2): 5′-GTAACCCGT 
TGAACCCCATT-3′, 5′-CCATCCAATCGGTAGTAGC 
G-3′; MICAL2 (NM_014632.2) : 5′-CAACCCGTGT 
GTGTCTCATC-3′, 5′-GTGGATGCCTGGACAAAGT 
T-3′; SNAI1 (NM_005985.3): 5′-AATCGGAAGCCTA 
ACTACAGCG-3′, 5′-GTCCCAGATGAGCATTGGCA-3′; 
 SNAI2 (NM_003068.4): 5′-GACCCTGGTTGCTTCA 
AGGA-3′, 5′-TGTTGCAGTGAGGGCAAGAA-3′.
Primers were used at the following conditions: 2 
min at 95°C; 33 cycles of 30 sec at 95°C, 30 sec at 58°C, 
15 sec at 72°C; 5 min at 72°C. Amplicons were sequence-
verified (3730 DNA Analyzer automated sequencer, 
Applied Biosystems). 
For QRT-PCR on human cancer specimens, 
Hs01121791_m1 (human MICAL2) and Hs01111406_g1 
(human RPN1) TaqMan GeneSpecific Assays FAM dye-
labeled (Applied Biosystems) and TaqMan Universal PCR 
Master Mix (Applied Biosystems) were used. Human 
RPN1 was used as reference gene. RPN1 mRNA level 
variability was not higher than 2-fold in tumor (T) and 
normal (N) tissues. The reference gene for QRT-PCR on 
cancer cell lines was 18S5.
Western blotting, immunofluorescence, 
immunohistochemistry
Western blotting (WB) was performed according 
to standard protocols. Immunofluorescence (IF) analysis 
was performed as in [41]. Immunohistochemistry (IHC) 
was performed as in [42]. ICC with DAB staining was 
performed as in [43].
Cells fixed for IF analysis were incubated with 
primary and secondary antibody solutions, DAPI (Sigma-
Aldrich), and mounted in Aqua PolyMount (Polysciences, 
USA). 
IHC was performed as in [42] with avidin-biotin 
complex technique on paraffin embedded sections 
rehydrated and treated with H2O2 before incubation with 
primary and secondary antibody solutions, and pertinent 
substrate (CN/DAB Substrate Kit, Thermo Scientific), and 
finally mounted in Canada Balm (Bioptika). 
Primary antibodies for WB: rabbit polyclonal 
anti-MICAL2 (1:1000, generated and validated in our 
laboratory as in [44], see Supplementary Figure 1), anti-
CTNNB1 (1:1000, Thermo Scientific, USA), anti-vimentin 
V9 (1:5000, Sigma), anti-beta-actin (1:7000, Sigma-
Aldrich). Secondary antibodies: HRP-conjugated goat anti-
rabbit (Pierce); HRP-conjugated goat anti-mouse (Pierce).
Primary antibodies for IF: rabbit polyclonal 
anti-MICAL2 (1:1000, generated and validated in our 
laboratory as in [44], see Supplementary Figure 1), anti-E-
caderin PA5–27187 (1:100 Thermo Scientific, USA), anti-
ZO-1 40–2300 N-term (1:500, Invitrogen, USA), anti-HA 
(1:200, Sigma), anti-CTNNB1 (1:100, Thermo Scientific, 
USA), anti-vimentin VIM 13.2 (1:500, Sigma). Secondary 
antibodies: Goat anti-rabbit Alexa Fluor 488 (and 568, not 
shown): 1:1000 (Molecular Probes, USA). Rabbit anti-
mouse Alexa Fluor 568: 1:1000 (Molecular Probes, USA).
Primary antibodies for IHC: rabbit polyclonal anti-
MICAL2 (1:2500 or 1:1500, generated in our laboratory 
as in [44], see Supplementary Figure 1), anti Ki-67 
(Novocastra Reagents, Leica Biosystems, Australia), anti-
MICAL1 (1:100, Santa Cruz, USA), anti-MICAL3 (1:100, 
Santa Cruz, USA). Secondary antibodies provided by 
VECTASTAIN Elite ABC Kit (Vector Laboratories, USA).
C.V. and A.P. evaluated the results. The 
immunoreaction was evaluated in arbitrary units (a.u.) 
in a range from 0 a.u. to 4 a.u. on the bases of antigen-
positive cell percentage in the region of interest (0% = 0 
a.u.; 1%–25% = 1 a.u.; 26%–50% = 2 a.u.; 51%–75% = 3 
a.u.; 76%–100% = 4 a.u.). 
Staining of F-actin
F-actin was stained with 488 Acti-stain and 568 
Phalloidin (Cytoskeleton).
Cell circularity
After tracing manually the cell perimeters, cell 
circularity was measured using the circularity plugin built in 
ImageJ, according to the equation: Circularity C = 4πA/P2 
( P = cell perimeter, A = cell area). 
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Cell viability assay
Cell proliferation and viability were tested with 
manual counting and/or with colorimetric assay based on 
3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT, Sigma-Aldrich), starting from 103 cells, 
for 4 days. OD values at 590 nm (ETI-SYSTEM Fast 
Reader, Sorin Biomedica, Italy) were plotted against a cell 
line-specific reference curve to infer the corresponding 
cell number. 
2D cell adhesion and motility assays
Adhesion was evaluated according to standard 
protocols by plating 104 cells on vessels coated with 
0.1 μg/μl type-I collagen (Sigma-Aldrich). Cells were 
challenged after 1 hr (786-O) or 15 minutes (MERO-14) 
from plating, then colored with crystal-violet solution 
and read at 590 nm (ETI System Fast Reader, Sorin 
Biomedica, Italy). 
Chemotaxis assay was performed with a modified 
Boyden Chamber mounting 10 μm polycarbonate 
membrane (NeuroProbe, USA). 8 × 103 cells were seeded 
in the upper chamber with serum-free growth medium 
and incubated for 16 hrs. The lower chamber contained 
growth medium plus 10% FBS (or no FBS for negative 
control). Staining was performed with Diff-Quick (Medion 
Diagnostics, Switzerland). 
For chemokinesis assay, 2 × 103 cells were seeded 
in cell growth medium with 10% FBS. Live imaging was 
performed (15 hrs) with a microscope-fitting a custom-
made 5% CO2 incubation chamber. Directness represents a 
measure of the cell’s tendency to travel in a straight line. It 
is calculated as the ratio of the Euclidian distance and the 
accumulated distance in time: D = dE/dA. D = 1 indicates a 
straight-line migration between start and end points [45].
Velocity is the ratio between the accumulated 
distance and time (experiment duration): V = dA/T, where 
T = total experiment time.
3D invasion assays
3D spheroid invasion assay and 3D vertical assay 
were performed as in [46] starting with 5 × 104 cells 
embedded in droplets of RPMI-1640 (Sigma-Aldrich) and 
2.2 mg/ml type-I collagen (BD Biosciences), at pH 7.4. 
Z-stack images were captured every 50 μm. 
3D vertical assay [38] was performed starting with 
2 × 105 cells/ml resuspended in RPMI-1640 with 2.2 mg/
ml type-I collagen, at pH 7.4, and seeded in 50 μl-aliquots 
in wells pre-coated with 3% heat-inactivated BSA. Cells 
were stained with YoPro and photographed along Z-axes 
through high-density collagen-I. Z-stack images were 
captured each 5 μm from the well bottom, up to 120 μm 
upward, toward the chemoattractant. 
Image acquisition and processing
Images for analysis of IF and F-actin staining were 
acquired in z-stack with NIS-Elements software (Nikon) 
and deconvoluted with the associated deconvolution 
software package, using a fluorescence microscope Nikon 
Eclipse Ti (Nikon) equipped with 40x DIC M Plan Fluor 
objective (Nikon) and DS-Qi1Mc-U2 12 bit (Nikon) 
camera. 
Images of ICC on agar-embedded cells and of IHC: 
Olympus BX43 equipped with camera Olympus DV20 
and Cell Sens Dimension software.
Chemotaxis images: Zeiss Axioskop 40 microscope 
(Zeiss) equipped with 5x objective (Zeiss), through 
AxioCam MRc 12 bit camera (Zeiss) and AxioVision 
software (Zeiss).
Chemokinesis live imaging: Nikon Eclipse Ti 
microscope (Nikon) and ORCA camera (Hamamatsu) 
equipped with 20x Ph2 DM Plan Apo objective (Nikon) 
and NIS-Elements software (Nikon). Images were 
analyzed with Manual Tracking plugin of ImageJ suite 
(NIH, USA), following each individual cell to the end 
of the experiment or to mitosis. Data were analyzed with 
Chemotaxis and Migration Tool 2.0 (Ibidi).
3D matrix invasion assays: acquired with NIS-
Elements software (Nikon) and deconvoluted with the 
associated deconvolution software, using a Nikon Eclipse 
Ti microscope (Nikon). It was equipped with 4x Achromat 
objective (Nikon) and DS-Qi1Mc-U2 12 bit camera 
(Nikon) in case of spheroid assay; it was equipped with 
20x Ph2 DM Plan Apo objective (Nikon) and ORCA 
camera (Hamamatsu) in case of vertical assay. Image 
analysis was performed with ImageJ software (NIH, 
USA).
Statistical analysis
Data of protein IHC are indicated as mean ± SEM 
and analyzed with Student’s t test for paired samples. 
Data from gene expression analysis in cell lines 
and cell circularity, viability, adhesion, chemotaxis, 
chemokinesis and 3D matrix invasion assays were 
obtained from more than three independent experiments 
(each performed with triplicates). They are expressed as 
mean ± SEM and analyzed with one-way Anova test and 
Tukey’s Multiple Comparison post-hoc test. 
Gene expression analysis in patients’ samples 
(N versus T) was evaluated with the non-parametric Mann-
Whitney test. 
Protein expression correlation was analyzed with 
Pearson Correlation test, r = –0.6641.
Always, difference between means was judged 
statistically significant for p ≤ 0.05.
All statistical procedures were performed using 
GraphPad software.
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